New York AG Plies Third Pact Pushing DNA Testing On Supplement Firms
This article was originally published in The Rose Sheet
Executive Summary
NBTY notes that FDA regulations allow firms flexibility in test methodologies for ingredient identity and other testing required under the supplement GMP final rule, and industry stakeholders say compliance with the GMPs is the standard, not a state agency's preferences.